CTOs on the Move

Juno Therapeutics

www.junotherapeutics.com

 
Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body`s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Somatic Therapies

Somatic Therapies is a Grand Junction, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hexagon Bio

Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics.

Canadian Organic Sprout Company

Canadian Organic Sprout Company is a Belleville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aderans Research Institute

Aderans Research Institute is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tonix Pharmaceuticals

Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.